While many other angiogenic targets besides VEGF and VEGFR2 are currently under clinical evaluations, the VEGF/VEGFR2 pathway still represents one of the most important vascular targets and thus further improvements on existing VEGF‐based therapies are likely to provide more rapid advances in standard care for many cancer patients. The gene discussed is KDR; the disease is cancer.